Drug Trial Radar · NCT05300048
Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
34
Actual
Start
Apr 22, 2022
Primary completion
Apr 30, 2025
Study completion Apr 30, 2025
Sponsor
- Lead sponsor
- Faeth TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side effects and enhancing anticancer activity.
Conditions
- Advanced Solid Tumor
- PIK3CA Mutation
- PTEN Loss of Function Mutation
Interventions
SerabelisibDrug
serabelisib administered orally
Insulin Suppressing DietOther
3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs
Nab paclitaxelDrug
nab-paclitaxel administered intravenously weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohorts 1a/1b: Evaluate safetyTime frame: Through study completion, up to 12 months.
- Cohorts 1a/1b: Evaluate complianceTime frame: Through study completion, up to 12 months.
- Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring Cmax.Time frame: Through study completion, up to 12 months.
- Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring Tmax.Time frame: Through study completion, up to 12 months.
- Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring AUC.Time frame: Through study completion, up to 12 months.
- Cohorts 2, 3, 4: Use the Objective Response Rate (ORR) to assess the antitumor efficacy of serabelisib in combination with a Study ISD.Time frame: Through study completion, an average of 8 months.
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
Pacific Cancer Specialists
Anaheim, California
Valkyrie Clinical Trials
Los Angeles, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Community Health Network, Inc.
Indianapolis, Indiana
Mayo Clinic - Rochester
Rochester, Minnesota
New Jersey Cancer Care, PA
Belleville, New Jersey
Englewood Health
Englewood, New Jersey
Northwell Health
Lake Success, New York
Memorial Sloan Kettering Cancer Center
New York, New York
East Carolina University
Greenville, North Carolina
University of Pennsylvania Health System, Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania
Avera Cancer Institute
Sioux Falls, South Dakota
Baptist Hospitals of Southeast Texas
Beaumont, Texas
Oncology Consultants, PA
Houston, Texas
Lumi Research
Kingwood, Texas
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.